NCT04997330

Brief Summary

High frequency repetitive transcranial magnetic stimulation (HF-rTMS) over dorsolateral prefrontal cortex (DLPFC) could correct defective executive functions over the hyperactive reward circuit through the meso-fronto-limbic connections. The restored cortical inhibitory control over compulsive alcohol use, could improve abstinence after withdrawal. The goal of this study is to evaluate the efficacy of HF-rTMS over DLPFC in AUD patients with executive dysfunction after withdrawal.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
95

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Sep 2021

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 31, 2021

Completed
9 days until next milestone

First Posted

Study publicly available on registry

August 9, 2021

Completed
23 days until next milestone

Study Start

First participant enrolled

September 1, 2021

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2023

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2023

Completed
Last Updated

August 30, 2021

Status Verified

March 1, 2021

Enrollment Period

1.7 years

First QC Date

July 31, 2021

Last Update Submit

August 27, 2021

Conditions

Keywords

alcoolrTMSexecutivedysfunctionaddiction

Outcome Measures

Primary Outcomes (1)

  • Percentage of participants with continuous complete alcohol abstinence

    Percentage of patients with continuous complete abstinence up to one month after the end of the rTMS treatment. The abstinence will be assessed using the Alcohol-Time Line Follow Back tool (TLFB). The Alcohol TLFB is a descriptive questionnaire, using a calendar, participants will retrospectively record at M1 the number of days they drank over the 30 days following the end of the rTMS treatment. Continuous complete abstinence will be defined as no day with alcohol consumption over the 30 days.

    1 month after the end of rTMS sessions

Secondary Outcomes (28)

  • Percentage of participants with alcohol continuous complete abstinence

    3 months after the end of rTMS sessions

  • Number of cumulative abstinence days

    1 month after the end of rTMS sessions

  • Number of cumulative abstinence days

    3 months after the end of rTMS sessions

  • Time until the first heavy drinking days (HDD)

    3 months after the end of rTMS sessions

  • Number of heavy drinking days (HDD)

    1 month after the end of rTMS sessions

  • +23 more secondary outcomes

Study Arms (2)

Active rTMS

EXPERIMENTAL

Bilateral high frequency (20Hz) Repetitive Transcranial Magnetic Stimulation (rTMS) over DLPFC

Device: Active rTMS

Sham rTMS

PLACEBO COMPARATOR

Sham bilateral high frequency (20Hz) Repetitive Transcranial Magnetic Stimulation (rTMS) over DLPFC

Device: Sham rTMS

Interventions

Bilateral high frequency (20Hz) rTMS will be delivered (over dorsolateral prefrontal cortex), at two daily sessions (left side on the morning and right side on the afternoon), 10 consecutive days on working day, 1500 pulses/session, 110% of motor threshold determined, 30 trains, 50 pulses per train and 15s inter train. A session will typically last around 10 minutes. Alcohol cues consisted of a selection of 60 alcohol-related pictures (beverage, drinking-related behaviors, alcohol-related cues) from the Geneva Appetitive alcohol Pictures will be presented during each rTMS session.

Also known as: Experimental group
Active rTMS
Sham rTMSDEVICE

Sham rTMS will be delivered (over dorsolateral prefrontal cortex) , at two daily sessions (left side on the morning and right side on the afternoon), 10 consecutive working days. A session will typically last around 10 minutes. Alcohol cues consisted of a selection of 60 alcohol-related pictures (beverage, drinking-related behaviors, alcohol-related cues) from the Geneva Appetitive alcohol Pictures will be presented during each rTMS session.

Also known as: Control group
Sham rTMS

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age between 18-75 years
  • Alcohol use disorder according to DSM 5, moderate to mild according to ADS
  • Residential stay for alcohol detoxofication

You may not qualify if:

  • Cognitive deficits defined by MoCA \<25 (Montreal Cognitive Assessment) performed at least 7days after alcohol detoxification and after at least 12 hours after benzodiazepine cessation
  • History of cerebral stroke
  • DSM-5 substance use disorders other than nicotine and alcohol
  • Contraindication for rTMS :
  • Pregnancy
  • History of epilepsy or seizure
  • Cochlear implants
  • Cardiac pacemaker or intracardiac lines, or metal in the body
  • Clinical history of complicated withdrawal symptoms
  • History of severe head trauma followed by loss of consciousness
  • Actual major depressive episode, schizophrenia according to the MINI (Mini International Neuropsychiatric Interview)
  • Breastfeeding women
  • Actual or history of organic failure including cirrhosis
  • Absence of health insurance; or patient with AME
  • Legal protection (curatorship or tutorship)
  • +6 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hôpital Universitaire Pitié-Salpêtrière

Paris, 75013, France

Location

MeSH Terms

Conditions

Behavior, Addictive

Interventions

Control Groups

Condition Hierarchy (Ancestors)

Compulsive BehaviorImpulsive BehaviorBehavior

Intervention Hierarchy (Ancestors)

Epidemiologic Research DesignEpidemiologic MethodsInvestigative TechniquesResearch DesignMethods

Study Officials

  • Fanny LEVY, Docteur

    Assistance Publique - Hôpitaux de Paris

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Fanny LEVY, Docteur

CONTACT

Romain ICICK, Docteur

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Masking Details
Double Blind
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 31, 2021

First Posted

August 9, 2021

Study Start

September 1, 2021

Primary Completion

May 1, 2023

Study Completion

July 1, 2023

Last Updated

August 30, 2021

Record last verified: 2021-03

Data Sharing

IPD Sharing
Will share

Data are available upon reasonable request. The procedures carried out with the French data privacy authority (CNIL, Commission nationale de l'informatique et des libertés) do not provide for the transmission of the database, nor do the information and consent documents signed by the patients. Consultation by the editorial board or interested researchers of individual participant data that underlie the results reported in the article after deidentification may nevertheless be considered, subject to prior determination of the terms and conditions of such consultation and in respect for compliance with the applicable regulations.

Shared Documents
STUDY PROTOCOL, SAP, ICF
Time Frame
Beginning 3 months and ending 3 years following article publication. Requests out of these time frame can also be submitted to the sponsor
Access Criteria
Researchers who provide a methodologically sound proposal

Locations